Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest of Keenova Therapeutics plc from 27 Dec 2019 to 26 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
Summary
Keenova Therapeutics plc quarterly and annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD history and change rate from 27 Dec 2019 to 26 Sep 2025.
  • Keenova Therapeutics plc Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending 26 Sep 2025 was $327,000,000, a 1621% decline year-over-year.
  • Keenova Therapeutics plc Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the twelve months ending 26 Sep 2025 was $391,300,000.
  • Keenova Therapeutics plc annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2024 was $614,500,000.
  • Keenova Therapeutics plc annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2021 was $829,800,000, a 14% increase from 2020.
  • Keenova Therapeutics plc annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2020 was $960,800,000, a 40% increase from 2019.
Source SEC data
View on sec.gov
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Trailing 12 Months (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Quarterly Change (%)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Annual (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Annual Change (%)

Keenova Therapeutics plc Quarterly Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $391,300,000 $327,000,000 -$308,000,000 -1621% 28 Jun 2025 26 Sep 2025 10-Q 10 Nov 2025 2025 Q3
Q2 2025 $699,300,000 $13,000,000 +$42,500,000 29 Mar 2025 27 Jun 2025 10-Q 06 Aug 2025 2025 Q2
Q1 2025 $656,800,000 $24,000,000 +$42,300,000 +64% 28 Dec 2024 28 Mar 2025 10-Q 12 May 2025 2025 Q1
Q4 2024 $614,500,000 $729,300,000 +$775,500,000 28 Sep 2024 27 Dec 2024 10-K 13 Mar 2025 2024 FY
Q3 2024 $161,000,000 $19,000,000 +$1,695,100,000 +99% 29 Jun 2024 27 Sep 2024 10-Q 10 Nov 2025 2025 Q3
Q2 2024 $1,856,100,000 $29,500,000 +$190,200,000 +87% 30 Mar 2024 28 Jun 2024 10-Q 06 Aug 2025 2025 Q2
Q1 2024 $2,046,300,000 $66,300,000 +$213,800,000 +76% 30 Dec 2023 29 Mar 2024 10-Q 12 May 2025 2025 Q1
Q4 2023 $46,200,000 15 Nov 2023 29 Dec 2023 10-K 13 Mar 2025 2024 FY
Q3 2023 $1,714,100,000 -$1,403,900,000 -453% 01 Jul 2023 29 Sep 2023 10-Q 05 Nov 2024 2024 Q3
Q2 2023 $219,700,000 -$146,300,000 -199% 01 Apr 2023 30 Jun 2023 10-Q 06 Aug 2024 2024 Q2
Q1 2023 $280,100,000 -$154,000,000 -122% 31 Dec 2022 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q3 2022 $738,200,000 $310,200,000 -$9,200,000 -3.1% 02 Jul 2022 30 Sep 2022 10-Q 07 Nov 2023 2023 Q3
Q2 2022 $73,400,000 +$66,300,000 +47% 17 Jun 2022 01 Jul 2022 10-Q 09 Aug 2023 2023 Q2
Q2 2022 $729,000,000 $685,200,000 -$545,500,000 -390% 02 Apr 2022 16 Jun 2022 10-Q 09 Aug 2023 2023 Q2
Q1 2022 $795,300,000 $126,100,000 +$34,500,000 +21% 01 Jan 2022 01 Apr 2022 10-Q 09 May 2023 2023 Q1
Q4 2021 $829,800,000 $228,500,000 25 Sep 2021 31 Dec 2021 10-K 26 Mar 2024 2023 FY
Q3 2021 $301,000,000 -$281,200,000 -1420% 26 Jun 2021 24 Sep 2021 10-Q 08 Nov 2022 2022 Q3
Q2 2021 $139,700,000 27 Mar 2021 25 Jun 2021 10-Q 11 Aug 2022 2022 Q2
Q1 2021 $160,600,000 26 Dec 2020 26 Mar 2021 10-Q 03 May 2022 2022 Q1
Q3 2020 $19,800,000 27 Jun 2020 25 Sep 2020 10-Q 02 Nov 2021 2021 Q3

Keenova Therapeutics plc Annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $614,500,000 30 Dec 2023 27 Dec 2024 10-K 13 Mar 2025 2024 FY
2021 $829,800,000 +$131,000,000 +14% 26 Dec 2020 31 Dec 2021 10-K 26 Mar 2024 2023 FY
2020 $960,800,000 +$630,700,000 +40% 28 Dec 2019 25 Dec 2020 10-K 03 Mar 2023 2022 FY
2019 $1,591,500,000 29 Dec 2018 27 Dec 2019 10-K 15 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.